JENSEN MICHAEL VANGSTED 4
4 · SYNLOGIC, INC. · Filed Nov 14, 2023
Insider Transaction Report
Form 4
SYNLOGIC, INC.SYBX
JENSEN MICHAEL VANGSTED
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-11-10−15,332→ 0 totalExercise: $33.45Exp: 2032-03-03→ Common Stock (15,332 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-11-10−13,332→ 0 totalExercise: $9.30Exp: 2033-03-16→ Common Stock (13,332 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-11-10−6,666→ 0 totalExercise: $9.30Exp: 2033-03-16→ Common Stock (6,666 underlying) - Award
Stock Option (right to buy)
2023-11-10+15,332→ 15,332 totalExercise: $1.85Exp: 2032-03-03→ Common Stock (15,332 underlying) - Award
Stock Option (right to buy)
2023-11-10+13,332→ 13,332 totalExercise: $1.85Exp: 2033-03-16→ Common Stock (13,332 underlying) - Award
Stock Option (right to buy)
2023-11-10+6,666→ 6,666 totalExercise: $1.85Exp: 2033-03-16→ Common Stock (6,666 underlying)
Footnotes (4)
- [F1]In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
- [F2]These stock options vested 25% on the first anniversary of the March 3, 2022 grant date, and vest in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
- [F3]The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
- [F4]These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.